Organization Overview
Alternative names
fostamatinib (2018 NDA)
olutasidenib (Rezlidhia) (2022 NDA)
Anemia (Phase 3)
Anemia, Hemolytic (Phase 3)
Anemia, Hemolytic, Autoimmune (Phase 3)
Arthritis (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1)
Coronavirus Infections (Phase 3)
Dry Eye Syndromes (Phase 2)
Glomerulonephritis, IGA (Phase 2)
Graft vs Host Disease (Phase 2)
Hemolysis (Phase 3)
Keratoconjunctivitis (Phase 2)
Keratoconjunctivitis Sicca (Phase 2)
Kidney Diseases (Phase 2)
Lupus Erythematosus, Discoid (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, T-Cell (Phase 2)
Ovarian Neoplasms (Phase 1)
Pneumonia (Phase 3)
Pneumonia, Viral (Phase 3)
Primary Myelofibrosis (Phase 2)
Purpura (Phase 3)
Purpura, Thrombocytopenic (Phase 3)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Rhinitis (Phase 2)
Rhinitis, Allergic (Phase 2)
Rhinitis, Allergic, Seasonal (Phase 2)
Severe Acute Respiratory Syndrome (Phase 3)
Thrombocytopenia (Phase 2)